InvestorsHub Logo
Followers 4
Posts 171
Boards Moderated 0
Alias Born 03/02/2015

Re: None

Monday, 04/19/2021 11:46:22 AM

Monday, April 19, 2021 11:46:22 AM

Post# of 918
OTLK COMMERCIAL PLANNING ACTIVITIES UNDERWAY
With an enhanced safety and cost-effectiveness profile, Outlook Therapeutics expects ONS-5010 to be widely adopted by payors and clinicians worldwide and to become the first-line drug of choice for payor-mandated “step edit” in the United States for retinal indications:
1) Physician and Patient Outreach
2) Aligning Key Opinion Leaders
3) Payor Community Engagement
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OTLK News